Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study

Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study

<i>Background and Objectives</i>: The treatment of chronic lymphocytic leukemia (CLL) has acquired new targeted therapies. In clinical trials, ibrutinib improved outcomes safely. Real-world data called for a reappraisal of ibrutinib strategies. We report on a single center’s experience w...

Full description

Bibliographic Details
Main Authors: Ana-Maria Moldovianu, Razvan Stoia, Mariana Vasilica, Iulia Ursuleac, Sorina Nicoleta Badelita, Andra Alina Tomescu, Oana Diana Preda, Alexandru Bardas, Mihaela Cirstea, Daniel Coriu
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Medicina
Subjects:
chronic lymphocytic leukemia (CLL)
ibrutinib
real-world
Bruton tyrosine kinase inhibitor
adverse events
Online Access:https://www.mdpi.com/1648-9144/59/2/324

Internet

https://www.mdpi.com/1648-9144/59/2/324

Similar Items